Barclays upgraded Summit Therapeutics (SMMT) to Equal Weight from Underweight with a price target of $18, up from $16. The firm believes the company’s lung cancer updates in 2026 “will be meaningful.” It sees multiple upcoming opportunities for Summit in different tumor types.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Biotech Alert: Searches spiking for these stocks today
- Short Report: Sezzle short interest at record high
- Summit Therapeutics initiated with a Peer Perform at Wolfe Research
- Positive Outlook for Summit Therapeutics Amid Strategic Clinical Advancements
- Summit Therapeutics Reports Positive Phase III Trial Results